In the realm of locally advanced or metastatic NSCLC, the combination of PD-1 [5, 6] or PD-L1 [7] blockade plus chemotherapy has demonstrated marked enhancements in both the progression-free survival (PFS) and overall survival (OS), compared with chemotherapy alone in the first-line setting, irrespective of the PD-L1 percentage. The gene discussed is CD274; the disease is non-small cell lung carcinoma.